ZTS Q3 2026 Earnings Analysis
Q3 2026 revenue was $2.4B (-1% YoY); companion animal declined amid clinic visit weakness, while livestock grew 7%; FY revenue guidance $9.22-9.32B, EPS $6.25-6.35.
Key Metrics
Key Takeaways
- Clinic visits down 3% YTD pressured companion animal; livestock grew 7%; derm share loss slowed -7 to -4 points Q2-Q3.
- Full-year revenue guidance narrowed to $9.22-$9.32B; EPS guidance raised to $6.25-$6.35 on operational discipline.
- Cytopoint long-acting approval Q4 2026; Simparica Duo approval year-end; 2026 innovation milestones met.
Listen On
Available In
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Zoetis, ticker ZTS, and their third quarter 2026 results, which came out this morning.
Lots to unpack here — derm wars, screwworms, and a guy named Jay on his very first earnings call. Should be fun.
It will be. But first, our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Good, now let's get into it.
So Zoetis is the big animal health company — pet meds, livestock vaccines, diagnostics. Q3 revenue came in at $2.4 billion, down about 1% both reported and organically. That was basically in line with what management expected going in.
Adjusted EPS, though, actually ticked up 1% to $1.75, mostly thanks to a lower share count from buybacks, not operational strength. So it's a bit of financial engineering helping the bottom line while the top line stays soft.
Right, and the U.S. segment was the weak spot — down 6% to $1.2 billion. International was actually the bright spot, up 4% to $1.1 billion, with livestock, parasiticides, and OA pain more than offsetting dermatology headwinds overseas.
And dermatology is really the story of this quarter. Key derm sales fell 16% globally to $396 million. In the U.S., Apoquel lost share to new competitors, though the chewable version is now half of Apoquel's volume, which shows some stickiness there.
And Cytopoint actually held up better than expected — management said the new injectable competitor's impact was minimal so far, partly because that competitor has had supply issues.
Here's a stat that stuck with me: U.S. canine visits were down about 5%, pruritic — meaning itchy-skin — visits down 3%. So it's not just competition, it's genuinely softer clinic traffic. Pet owners are being more careful with spending.
Which ties into something CEO Kristin Peck mentioned — vet service costs are up 50% since 2022, way outpacing general inflation. That's squeezing pet owners and changing behavior.
Right, and even the pet population mix is shifting — more cats, fewer dogs, because of housing costs affecting adoption. Dogs are more "medicalized," as they put it, so that mix shift actually weighs on demand for vet services overall.
Now, the good news: management said their defensive playbook is working. They used targeted promotional spending — what they call "gross-to-net" investments rather than cutting list prices — to slow the bleeding. Derm share loss improved from 7 points lost in Q2 to just 4 points in Q3.
And in parasiticides, Simparica Trio held its U.S. share at 22.5%, still roughly double the next competitor, and they remain the leader in new puppy starts, which is a nice leading indicator for future sales.
On the innovation front, there's real stuff coming. Long-acting Cytopoint is expected to get FDA approval in Q4, launching in the first half of 2027. Simparica Duo approval is now expected by year-end, ahead of schedule.
And don't skip over livestock — that segment grew 7% to $797 million, with strength in cattle, swine, poultry vaccines, and even fish vaccines in Norway. Global protein demand is just a steady tailwind there, offsetting the companion animal softness nicely. Diversification is really earning its keep this quarter.
Diagnostics also grew double digits — 13% to $122 million — boosted by the VitalRADS and VPG acquisitions plus organic adoption of their point-of-care platforms.
Now let's talk guidance, because this is where it gets interesting. Zoetis narrowed full-year revenue guidance to $9.22 to $9.32 billion — essentially the higher end of their prior range — while actually raising adjusted EPS guidance to $6.25 to $6.35. That's a signal of confidence even amid a tough top line.
On the call, new CFO Jay Saccaro — his first earnings call with the company — was pretty candid about 2027. He basically said: don't expect us to assume the macro environment improves, don't expect competitive pressure to ease, and don't expect big revenue contribution from new pipeline products next year. The bigger innovation payoff is 2028 and beyond.
That's a refreshingly conservative tone for a new CFO. He's not overpromising. Analysts pushed on this in Q&A — JPMorgan's Chris Schott specifically asked if the Street's current estimates were reasonable, and Saccaro wouldn't bite, just reiterated they're being "prudent."
One other Q&A moment worth flagging — someone asked about the upcoming Befrena launch, a competing long-acting derm product expected in 2027. Peck framed Zoetis's own long-acting Cytopoint as both a defensive and offensive move — convenience for pet owners, and a way to expand the category rather than just defend share.
And on margins, gross margin dipped slightly to 71%, pressured by those gross-to-net promotional investments and some mix effects, partially offset by tariff refunds. Operating expenses stayed flat, with cost discipline — lower incentive comp, productivity programs — offsetting increased R&D spend on digital and pipeline projects.
So bottom line for investors: this was a "meet expectations, not beat them" quarter on revenue, but EPS and margin discipline were better than feared. The real debate is whether the dermatology and parasiticide share losses are truly stabilizing, or whether management is just buying time with promotional spending.
Right — and before we wrap, our standard reminder: Everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Looking ahead, the next few quarters are really about watching two things: does derm share loss actually hit zero and start growing again, and how much of that 2027 innovation pipeline — long-acting Cytopoint, Simparica Duo, Lenivia's U.S. launch — actually shows up in the numbers.
Livestock and diagnostics look like they'll keep carrying the load in the meantime. It's a company leaning on diversification while it fights through a genuinely tough companion animal cycle.
That's it for this episode of Beta Finch. Thanks for listening, and we'll catch you next time as we break down another earnings call.
See you then!